MARKET

EXEL

EXEL

Exelixis Inc
NASDAQ
59.01
-0.12
-0.20%
After Hours: 59.00 -0.01 -0.02% 19:46 09/04 EDT
OPEN
58.50
PREV CLOSE
59.13
HIGH
59.26
LOW
58.46
VOLUME
1.58M
TURNOVER
--
52 WEEK HIGH
59.72
52 WEEK LOW
33.76
MARKET CAP
14.62B
P/E (TTM)
18.53
1D
5D
1M
3M
1Y
5Y
1D
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
NASDAQ · 3d ago
Biotech Stocks At 52-Week Highs - OABI +13%, FRNM, EXEL, FTH, LFST
NASDAQ · 4d ago
Exelixis (EXEL) Secures CABOMETYX Patent Win Through 2030
Simply Wall St · 5d ago
Guggenheim Remains a Hold on Exelixis (EXEL)
TipRanks · 6d ago
Exelixis: "Hold" On Zanzalintinib Subpopulation Miss And STELLAR-304 2H 2026 Data
Seeking Alpha · 6d ago
Exelixis (EXEL) Receives a Hold from BMO Capital
TipRanks · 6d ago
Exelixis Secures Key Patent Victory, Extends Exclusivity
TipRanks · 08/31 20:53
Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know
Seeking Alpha · 08/31 18:57
More
About EXEL
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Webull offers Exelixis Inc stock information, including NASDAQ: EXEL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXEL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXEL stock methods without spending real money on the virtual paper trading platform.